{"id":390280,"date":"2020-02-03T00:00:00","date_gmt":"2020-02-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/emthim0030-2020-biopharma-psoriasis-emerging-therapies-risankizumab-abbv-066-us-wave-2-2020\/"},"modified":"2026-03-31T10:45:43","modified_gmt":"2026-03-31T10:45:43","slug":"emthim0030-2020-biopharma-psoriasis-emerging-therapies-risankizumab-abbv-066-us-wave-2-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/emthim0030-2020-biopharma-psoriasis-emerging-therapies-risankizumab-abbv-066-us-wave-2-2020\/","title":{"rendered":"Psoriasis | Emerging Therapies | Risankizumab (ABBV-066) | US | Wave 2 | 2020"},"content":{"rendered":"<p>In the past decade, the TNF-\u03b1 inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12\/23 inhibitor Stelara (Janssen) have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents, including the IL-17 inhibitors\u2014Novartis\u2019s Cosentyx in 2015, Eli Lilly\u2019s Taltz in 2016, and Valeant\u2019s Siliq in 2017\u2014and the IL-23 inhibitors\u2014Janssen\u2019s Tremfya in 2017 and Sun Pharma\u2019s Ilumya in 2018\u2014has substantially altered the moderate to severe psoriasis market landscape. This series includes three waves that track the awareness, trial, and usage of AbbVie\u2019s Skyrizi following its May 2019 launch for psoriasis. In addition, the series examines physician-anticipated trends in moderate to severe psoriasis treatment and, in particular, Skyrizi\u2019s uptake; it also assesses AbbVie\u2019s promotional efforts around the drug.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>How quickly are U.S. dermatologists adopting Skyrizi, and what percentage of their psoriasis patients do they consider candidates for the drug?<\/li>\n<li>When and for which patients are dermatologists prescribing Skyrizi, what are the reasons for prescribing, and how satisfied are they with the drug?<\/li>\n<li>How do prescribers and nonprescribers of Skyrizi compare across key metrics?<\/li>\n<li>What promotional messages and activities are AbbVie employing in support of the launch of Skyrizi?<\/li>\n<\/ul>\n<p><strong>Geography<\/strong><\/p>\n<p>United States<\/p>\n<p><strong>Primary Research<\/strong><\/p>\n<p>Survey of 75 U.S. dermatologists for each wave<\/p>\n<p><strong>Key metrics included <\/strong><\/p>\n<p>Unaided and aided awareness of Skyrizi<\/p>\n<p>Familiarity with and impressions of Skyrizi<\/p>\n<p>Prescriber and nonprescriber profiles<\/p>\n<p>Willingness to prescribe Skyrizi<\/p>\n<p>Performance of Skyrizi on key attributes<\/p>\n<p>Sales representative visit frequency, reach, and effectiveness<\/p>\n<p>Benchmarking against previously launched psoriasis agents<\/p>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p>Emerging Therapies captures U.S. physicians\u2019 awareness, perceptions, and usage of the launched product at one, six, and twelve months postlaunch, as well as the current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, benchmarking against other launched agents, along with statistical comparative analysis with prior waves so that marketers can track and optimize the effectiveness of their launch strategy or fine-tune their product positioning to counter its impact on their brand\u2019s share.<\/p>\n","protected":false},"template":"","class_list":["post-390280","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-product-emerging-therapies","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390280\/revisions"}],"predecessor-version":[{"id":393405,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390280\/revisions\/393405"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}